STOCKS

Joon Choi

Senior Portfolio Manager, Research Analyst,

Signalert Asset Management LLC

  • Sr. Portfolio Manager at Signalert Asset Management
  • Over 19 Years Industry Experience
  • Research Analyst and Signalert Asset Management

About Joon

In addition to the daily portfolio management of Signalert's investment partnerships, Joon serves as a research analyst to perform fundamental and quantitative analyses of both equity and bond markets. He also works with the director of research in order to formulate the investment strategies that we utilize in managing client accounts. He has 19 years of industry experience, and 15 years of experience at Signalert. He graduated from Colgate University with a BA degree in economics. He later earned his MBA in finance from New York University. He is also fluent in Korean.

Joon's Articles

Over 92% of the companies in the S&P 500 Index (SPX) have reported third quarter earnings so far and 80.4% of them reported above analysts’ estimates, states Joon Choi of Signalalert Asset Management.
Although large-cap value stocks (IVE) outperformed their growth counterparts (IVW) by 8% (18% vs 10%) from the beginning of the year through June 11, they have underperformed by 13% since (3% vs 16%), states Joon Choi of Signalalert Asset Management.
There are many types of momentum equity strategies with varying effectiveness. The death cross is a well-known concept where you buy a product when its 50-day moving average crosses above the 200-day moving average and sell when the reverse occurs, states Joon Choi of Signalalert Asset Management.
The biotech sector fared well last year as SPDR Biotech ETF (XBI) (equal-weight ETF) gained 48.3% while its market-weight counterpart iShares Nasdaq Biotechnology Index Fund (IBB) only gained 26%, both still out-pacing SPY’s 18.4% gain, states Joon Choi of Signalalert Asset Management.